Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2 is reflected on the page. This is a technical update with no substantive changes to study data or displayed information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T11:49:46.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-05T15:15:26.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T03:30:05.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    Added a dedicated Locations section featuring Colorado as a study site and updated the page revision to v3.3.3; removed the Colorado Locations and HHS Vulnerability Disclosure items (and the older Revision: v3.3.2 reference).
    Difference
    0.2%
    Check dated 2025-12-24T15:27:52.000Z thumbnail image
  6. Check
    91 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added and Revision: v3.2.0 was removed in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T14:53:54.000Z thumbnail image
  7. Check
    99 days ago
    Change Detected
    Summary
    Removed the government funding lapse and operating status notice from the page. The study details, eligibility criteria, locations, and results plan remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-18T07:36:18.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.